FGEN FibroGen Inc.

FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 3:30 PM Eastern Time. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at A replay of the webcast will be available for 30 days.

About FibroGen

FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), is approved by the National Medical Products Administration (NMPA) in China for CKD patients on dialysis and not on dialysis, and by the Ministry of Health, Labour and Welfare (MHLW) in Japan for CKD patients on dialysis. The NDA for roxadustat for treatment of CKD anemia was submitted to the U.S. FDA in December 2019. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit .

Contact:

FibroGen, Inc.

Media Inquiries:

Sara Iacovino

1.703.474.4452

Investors:

Michael Tung, M.D.

Investor Relations

1.415.978.1433

Source: FibroGen, Inc

EN
11/02/2020

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelod...

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS). “The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatm...

December 15, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York. FibroGen’s management team wi...

December 2, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports Third Quarter 2025 Financial Results and Provides Bus...

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood...

November 10, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report Third Quarter 2025 Financial Results

FibroGen to Report Third Quarter 2025 Financial Results SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update....

November 3, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Cl...

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as a companion PET imaging agent and a potential predictive patient selection biomarker Interim analysis expected in 2H 2026 SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc....

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch